SmarterAnalyst, 30 April 2020
In a report released today, Andrew Fein from H.C. Wainwright maintained a Buy rating on Vertex Pharmaceuticals (), with a price target of $295.00. The company’s shares closed last Wednesday at $251.05.
According to TipRanks.com, Fein is a 5-star analyst with an average return of 8.9% and a 48.1% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Constellation Pharmaceuticals, and Proteostasis Therapeutics.